Hrt Financial LP Allovir, Inc. Transaction History

Hrt Financial LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	BUY	$4.7 - $9.98 $225,731 - $479,319	48,028 New	48,028 $246,000
Q2 2022 Aug 12, 2022	BUY	$3.26 - $7.06 $96,815 - $209,667	29,698 Added 214.4%	43,550 $169,000
Q1 2022 May 16, 2022	BUY	$6.75 - $13.52 $93,501 - $187,279	13,852 New	13,852 $93,000
Q3 2021 Nov 15, 2021	SELL	$16.97 - $25.06 $1.36 Million - $2.01 Million	-80,181 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$19.44 - $25.06 $1.56 Million - $2.01 Million	80,181 New	80,181 $1.58 Million

44.6M

14.9K

200

Ticker ALVR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,063,400
Market Cap $40.9M
Description
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.